Relationship of Liver Disease Stage and Antiviral Therapy With Liver-Related Events and Death in Adults Coinfected With HIV/HCV

Authors:
  • SMShruti H. Mehta
    Shruti H. Mehta
  • CSCatherine G. Sutcliffe
    Catherine G. Sutcliffe
  • YHYvonne M. Higgins
    Yvonne M. Higgins
  • MTMichael S. Torbenson
    Michael S. Torbenson
  • SBSherilyn C. Brinkley
    Sherilyn C. Brinkley
  • RMRichard D. Moore
    Richard D. Moore
  • DTDavid L. Thomas
    David L. Thomas

Abstract
Hepatitis C virus (HCV) coinfection occurs frequently in persons infected with the human immunodeficiency virus (HIV) because of shared routes of acquisition.1,2 In the setting of effective HIV antiretroviral therapy (ART), the presence of HCV infection has been associated with an increased risk of death compared with those with HIV monoinfection. For example, in the North American AIDS Cohort Collaboration on Research and Design, HCV coinfected persons had an 85% greater risk of death.3 Furthermore, in other cohort studies, HCV-related liver disease has emerged as a leading cause of morbidity and mortality in coinfected persons due, in part, to more rapid progression of liver disease with concurrent HIV infection; however, whether the risk of clinical outcomes differs by the liver fibrosis stage is unknown.4-8

This publication has 33 references indexed in Scilit: